Erbitux cetuximab: Additional Phase III data

Additional data from the open-label, Chinese Phase III TAILOR trial in 397 patients with wild-type Ras mCRC showed that first-line treatment with Erbitux plus FOLFOX-4

Read the full 252 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE